Jeffrey William Henderson Purchases 1,500 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) Director Jeffrey William Henderson bought 1,500 shares of Becton, Dickinson and Company stock in a transaction dated Monday, February 10th. The shares were bought at an average price of $233.62 per share, for a total transaction of $350,430.00. Following the completion of the transaction, the director now directly owns 8,015 shares of the company’s stock, valued at $1,872,464.30. This represents a 23.02 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link.

Becton, Dickinson and Company Stock Down 0.0 %

Shares of Becton, Dickinson and Company stock opened at $229.50 on Wednesday. The business has a fifty day simple moving average of $232.20 and a 200 day simple moving average of $233.99. The stock has a market cap of $66.56 billion, a PE ratio of 38.12, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40. The company has a quick ratio of 0.74, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Research analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company declared that its board has authorized a stock buyback plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.81%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Institutional Investors Weigh In On Becton, Dickinson and Company

Large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its holdings in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after purchasing an additional 1,317,723 shares in the last quarter. First Eagle Investment Management LLC grew its holdings in shares of Becton, Dickinson and Company by 31.4% during the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier’s stock worth $1,004,132,000 after buying an additional 1,057,879 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Becton, Dickinson and Company in the 4th quarter valued at approximately $181,279,000. Nordea Investment Management AB lifted its stake in Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock valued at $647,082,000 after acquiring an additional 673,568 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Becton, Dickinson and Company by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after acquiring an additional 460,440 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the topic of several research reports. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler raised their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.